# US 2026/0209739 A1 · Nucleic acid molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0209739 A1
- Document ID: US20260209739A1
- Status: Published application
- Kind: A1
- Application number: 19/640,675
- Filed: 2026-04-07
- Published: 2026-07-23
- Earliest claimed: 2017-07-04
- Assignees: CureVac AG
- Applicants: CureVac SE
- Inventors: Mariola FOTIN-MLECZEK; Katja FIEDLER; Aleksandra KOWALCZYK; Regina HEIDENREICH
- Web page: https://patentgrep.com/patent/US20260209739A1

## CPC

- C12N 9/90: Isomerases (5.)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0011: {Cancer antigens}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- C07K 14/70521: {CD28, CD152}
- C12Y 503/03012: L-Dopachrome isomerase (5.3.3.12)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/6031: {Proteins}
- A61K 2039/605: {MHC molecules or ligands thereof}
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides novel artificial nucleic acid molecules encoding at least one antigenic peptide or protein and at least one additional sequence preferably targeting the antigenic peptides or proteins to cellular compartments of interest. Further, the invention provides (pharmaceutical) compositions or vaccines and kits comprising said nucleic acid molecules. The nucleic acid molecules, (pharmaceutical) compositions or vaccines and kits are useful for treating a variety of diseases such as cancer, infectious diseases, autoimmune diseases, allergies or graft-versus host disease.

## Claims

### Claim 1

An artificial nucleic acid molecule comprising at least one coding region encoding
a. at least one antigenic peptide or protein,
and at least one additional amino acid sequence derived from at least one immune response activating signal transduction protein located in the external plasma membrane,
wherein said at least one additional amino acid sequence comprises or consists of at least one transmembrane domain.

### Claim 2 (depends on 1)

The artificial nucleic acid molecule according to claim 1, wherein said immune response activating signal transduction protein located in the external plasma membrane (IRSTepm) is selected from CTLA4 (Cytotoxic T-lymphocyte protein 4), CD36 (Platelet glycoprotein 4), TRBC2 (T-cell receptor beta-2 chain C region), TRDC (T-cell receptor delta chain C region), TLR4 (Toll-like receptor 4), CD4 (T-cell surface glycoprotein CD4), TRBC1 (T-cell receptor beta-1 chain C region), CD3E (T-cell surface glycoprotein CD3 epsilon chain), PTPRC (Receptor-type tyrosine-protein phosphatase C), FCG3A (Low affinity immunoglobulin gamma Fc region receptor LNP-III-A), CD28 (T-cell-specific surface glycoprotein CD28), CD79A (B-cell antigen receptor complex-associated protein alpha chain), CD19 (B-lymphocyte antigen CD19), NKG2D (NKG2-D type II integral membrane protein), FCERG (High affinity immunoglobulin epsilon receptor subunit gamma), CD79B (B-cell antigen receptor complex-associated protein beta chain), CD86 (T-lymphocyte activation antigen CD86), CD226 (CD226 antigen), MUC17 (Mucin-17), CD209 (CD209 antigen), TLR8 (Toll-like receptor 8), or a variant, fragment or derivative of any of these proteins.

### Claim 3 (depends on 1, 2)

The artificial nucleic acid molecule according to claim 1 or 2, wherein said at least one additional amino acid sequence further comprises
b. at least one cytoplasmic domain.

### Claim 4

The artificial nucleic acid molecule according to any one of the preceding claims, wherein said at least one coding region further encodes
c. at least one signal peptide.

### Claim 5

The artificial nucleic acid molecule according to any one of the preceding claims, wherein said at least one antigenic peptide or protein is selected from or derived from tumor antigens, viral, bacterial, protozoal, fungal or allogenic antigens.

### Claim 6 (depends on 5)

The artificial nucleic acid molecule according to claim 5, wherein said at least one antigenic peptide or protein comprises or consists of an amino acid sequence corresponding to any one of SEQ ID NOs: 3719-27945; 76420-76439, 76440-76474, or a fragment, variant or derivative thereof, and is optionally encoded by a nucleic acid sequence according to any one of SEQ ID NOs: 27946-52172; 76495-76514, 52173-76399; 76570-76589, 76515-76549, 76590-76624 or a fragment, variant or derivative of any one of said sequences.

### Claim 7 (depends on 5, 6)

The artificial nucleic acid molecule according to claim 5 or 6, wherein said tumor antigen is selected from BRAF, PIK3CA, KRAS, IDH1, TP53, NRAS, AKTI, SF3B1, CDKN2A, RPSAP58, EGFR, NY-ESO1, MUC-1, 5T4, Her2, MAGE-A3, LY6K, CEACAM6, CEA, MCAK, KK-LC1, Gastrin, VEGFR2, MMP-7, MPHOSPH1, MAGE-A4, MAGE-A1, MAGE-C1, PRAME, Survivin, MAGE-A9, MAGE-C2, FGFR2, WT1, PSA, PSMA, Prostate-specific antigen precursor, Kita-kyushu lung cancer antigen 1, Trophoblast glycoprotein, Cyclin-dependent kinase inhibitor 2A, Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3, multiple tumor suppressor 1/cyclin-dependent kinase 4 inhibitor p16, GTPase NRas or a fragment, variant or derivative of any of said tumor antigens, or any combination thereof.

### Claim 8

The artificial nucleic acid molecule according to any one of the preceding claims wherein said IRSTepm comprises or consists of an amino acid sequence corresponding to any one of SEQ ID NOs: 157-179, or a fragment, variant or derivative thereof, and is optionally encoded by a nucleic acid sequence corresponding to any one of SEQ ID NOs: 365-387, 573-595, 781-803, 989-1011, 1197-1219, 1405-1427, 1613-1635, 1821-1843, 2029-2051, 2237-2259, 2445-2467, 2653-2675, 2861-2883, or a fragment, variant or derivative of any one of said sequences.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The artificial nucleic acid molecule according to any one of claims 1 to 8, wherein the at least one additional amino acid sequence comprises or consists of at least one transmembrane domain and at least one cytoplasmic domain comprising or consisting of an amino acid sequence corresponding to any one of SEQ ID NOs: 76625-76647, or a fragment, variant or derivative thereof and is optionally encoded by a nucleic acid sequence corresponding to any one of SEQ ID NOs: 76648-76947, 77004-77017, 77066 or a fragment, variant or derivative of any one of said sequences.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The artificial nucleic acid molecule according to any one of claims 1 to 8, wherein the transmembrane domain comprises or consists of an amino acid sequence corresponding to any one of SEQ ID NOs: 180-208, or a fragment, variant or derivative thereof and is optionally encoded by a nucleic acid sequence corresponding to any one of SEQ ID NOs: 388-416, 596-624, 804-832, 1012-1040, 1220-1248, 1428-1456, 1636-1664, 1844-1872, 2052-2080, 2260-2288, 2468-2496, 2676-2704, 2884-2912, or a fragment, variant or derivative of any one of said sequences.

### Claim 11 (depends on 4, 5, 6, 7, 8, 9, 10)

The artificial nucleic acid molecule according to any one of claims 4 to 10, wherein the signal peptide comprises or consists of an amino acid sequence corresponding to any one of SEQ ID NOs: 1-156, 76948-76951, or a fragment, variant or derivative thereof, and is optionally encoded by a nucleic acid sequence according to any one of SEQ ID NOs: 209-364, 76952-76955, 625-780, 76960-76963, 833-988, 76964-76967, 417-572, 76956-76959, 1249-1404, 76972-76975, 1457-1612, 76976-76979, 1665-1820, 76980-76983, 1873-2028, 76984-76987, 2081-2236, 76988-76991, 2289-2444, 76992-76995, 2497-2652, 76996-76999, 2705-2860, 77000-77003, 1041-1196, or 76968-76971 or a fragment, variant or derivative thereof.

### Claim 12

The artificial nucleic acid molecule according to any one of the preceding claims, further encoding in its at least one coding region
d. at least one linker.

### Claim 13 (depends on 12)

The artificial nucleic acid molecule according to claim 12, wherein said linker is a non-immunogenic linker, optionally comprising or consisting of an amino acid sequence according to any one of SEQ ID NOs: 2937, 76400-76418, 77018-77058 optionally encoded by a nucleic acid sequence according to any one of SEQ ID NOs: 2936, 76494, 76569, 76475-76493, 76550-76568, 77059-77061 or a fragment, variant or derivative of any one of said sequences.

### Claim 14

The artificial nucleic acid molecule according to any one of the preceding claims, wherein said at least one coding region further encodes
e. at least one T helper epitope.

### Claim 15 (depends on 14)

The artificial nucleic acid molecule according to claim 14, wherein said helper epitope sequence comprises or consists of an amino acid sequence corresponding to any one of SEQ ID NOs: 3083-3294, or a fragment, variant or derivative thereof, and is optionally encoded by a nucleic acid sequence according to any one of SEQ ID NOs: 3295-3506, 3507-3718, or a fragment, variant or derivative of any one of said sequences.

### Claim 16 (depends on 5, 6, 7, 9, 10, 11, 13, 14, 15)

The artificial nucleic acid molecule according to any one of the preceding claims, comprising at least one coding region of the following Formula (I), preferably in 5′→3′ direction:
wherein
“SIG” encodes a signal peptide, preferably as defined in claim 11,
“L” encodes a linker sequence, preferably as defined in claim 13,
each “AN” encodes an identical or different antigenic peptide or protein, preferably as defined in claim 5, 6 or 7,
“IM” encodes a helper epitope, preferably as defined in claim 14 or 15,
“TMD/TMCD” encodes an amino acid sequence derived from an immune response signal transduction protein located in the external plasma membrane, preferably a transmembrane domain, preferably as defined in claim 10, and optionally a cytoplasmic domain, preferably as defined in claim 9
b, d, m, n, o is each independently an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10,
a, c, e, p is each independently an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.

### Claim 17 (depends on 5, 6)

The artificial nucleic acid molecule according to any one of the preceding claims, encoding in its at least one coding region at least one, or a plurality of at least two, three, four, five, six, seven, eight, nine or ten antigenic peptides or proteins, optionally selected from at least one antigenic peptide or protein according to claim 5 or 6, or fragment, variant or derivative thereof, or a combination of said antigenic peptides or proteins, or their fragments, variants or derivatives.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The artificial nucleic acid molecule according to any one of claims 1 to 17, wherein said artificial nucleic acid molecule is an RNA.

### Claim 19 (depends on 18)

The artificial nucleic acid molecule according to claim 18, wherein the RNA is an mRNA, a viral RNA, a replicon RNA, or a circular RNA.

### Claim 20

The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, wherein the artificial nucleic acid molecule is mono-, bi-, or multicistronic.

### Claim 21

The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, wherein said artificial nucleic acid molecule is modified, preferably stabilized.

### Claim 22

The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, wherein
the G/C content of the at least one coding region is increased compared to the G/C content of the corresponding coding sequence of the corresponding wild-type artificial nucleic acid, and/or wherein
the C content of the at least one coding region is increased compared to the C content of the corresponding coding sequence of the corresponding wild-type artificial nucleic acid, and/or wherein
the codons in the at least one coding region are adapted to human codon usage, wherein the codon adaptation index (CAI) is preferably increased or maximised in the at least one coding sequence of the artificial nucleic acid,
wherein the amino acid sequence encoded by the artificial nucleic acid is preferably not being modified compared to the amino acid sequence encoded by the corresponding wild-type artificial nucleic acid.

### Claim 23 (depends on 22)

The artificial nucleic acid molecule, preferably RNA, according to claim 22, wherein said at least one coding region comprises or consists of a nucleic acid sequence corresponding to any one of SEQ ID NOs: 417-2912, 76671-76947, 77004-77017, 77066.

### Claim 24

The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, which comprises a 5′-CAP structure, preferably m7GpppN or Cap1.

### Claim 25

The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, which comprises at least one histone stem-loop.

### Claim 26 (depends on 25)

The artificial nucleic acid molecule, preferably RNA, according to claim 25, wherein the at least one histone stem-loop comprises a nucleic acid sequence according to the following formulae (II) or (III):
wherein:
stem1 or stem2 bordering elements
is a consecutive sequence of 1 to 6, preferably of 2 to 6,
N1-6
more preferably of 2 to 5, even more preferably of 3 to 5,
most preferably of 4 to 5 or 5 N, wherein each N is
independently from another selected from a nucleotide
selected from A, U, T, G and C, or a nucleotide analogue
thereof;
stem1 [N0-2GN3-5]
is reverse complementary or partially reverse
complementary with element stem2, and is a
consecutive sequence between of 5 to 7 nucleotides;
wherein N0-2 is a consecutive sequence of 0 to 2,
preferably of 0 to 1, more preferably of 1 N, wherein
each N is independently from another selected from a
nucleotide selected from A, U, T, G and C or a
nucleotide analogue thereof;
wherein N3-5 is a consecutive sequence of 3 to 5,
preferably of 4 to 5, more preferably of 4 N, wherein
each N is independently from another selected from a
nucleotide selected from A, U, T, G and C or a
nucleotide analogue thereof, and
wherein G is guanosine or an analogue thereof, and
may be optionally replaced by a cytidine or an analogue
thereof, provided that its complementary nucleotide
cytidine in stem2 is replaced by guanosine;
loop sequence [N0-4(U/T)N0-4]
is located between elements stem1 and stem2, and is a
consecutive sequence of 3 to 5 nucleotides, more
preferably of 4 nucleotides;
wherein each N0-4 is independent from another a
consecutive sequence of 0 to 4, preferably of 1 to 3,
more preferably of 1 to 2 N, wherein each N is
independently from another selected from a nucleotide
selected from A, U, T, G and C or a nucleotide analogue
thereof; and
wherein U/T represents uridine, or optionally thymidine;
stem2 [N3-5CN0-2]
is reverse complementary or partially reverse
complementary with element stem1, and is a
consecutive sequence between of 5 to 7 nucleotides;
wherein N3-5 is a consecutive sequence of 3 to 5,
preferably of 4 to 5, more preferably of 4 N, wherein
each N is independently from another selected from a
nucleotide selected from A, U, T, G and C or a
nucleotide analogue thereof;
wherein N0-2 is a consecutive sequence of 0 to 2,
preferably of 0 to 1, more preferably of 1 N, wherein
each N is independently from another selected from a
nucleotide selected from A, U, T, G and C or a
nucleotide analogue thereof; and
wherein C is cytidine or an analogue thereof, and may
be optionally replaced by a guanosine or an analogue
thereof provided that its complementary nucleotide
guanosine in stem1 is replaced by cytidine;
wherein
stem1 and stem2 are capable of base pairing with each other
forming a reverse complementary sequence, wherein base pairing may occur between stem1 and stem2, or
forming a partially reverse complementary sequence, wherein an incomplete base pairing may occur between stem1 and stem2.

### Claim 27 (depends on 25, 26)

The artificial nucleic acid molecule, preferably RNA, according to claim 25 or 26, wherein the at least one histone stem-loop comprises a nucleic acid sequence according to the following formulae (IIa) or (IIIa):

### Claim 28

The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, optionally comprising a poly(A) sequence, preferably comprising 10 to 200, 10 to 100, 40 to 80 or 50 to 70 adenosine nucleotides.

### Claim 29

The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, optionally comprising a poly(C) sequence, preferably comprising 10 to 200, 10 to 100, 20 to 70, 20 to 60 or 10 to 40 cytosine nucleotides.

### Claim 30

The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, which comprises, preferably in 5′ to 3′ direction, the following elements:
a) a 5′-CAP structure, preferably m7GpppN, an ARCA Cap or Cap1
b) optionally a 5′-UTR element, preferably comprising or consisting of a nucleic acid sequence, corresponding to the nucleic acid sequence according to SEQ ID NOs: 3061 or 3063 or a fragment, variant or corresponding RNA sequence thereof,
c) at least one coding sequence as defined in any one of the preceding claims,
d) optionally a 3′-UTR element, preferably comprising or consisting of a nucleic acid sequence corresponding to the nucleic acid sequence according to SEQ ID NOs: 3065; 3067; 3069; 3071; 3073; 3075 or 3077, or a fragment, variant or corresponding RNA sequence thereof,
e) optionally a poly(A) tail, preferably consisting of 10 to 1000, 10 to 500, 10 to 300 10 to 200, 10 to 100, 40 to 80 or 50 to 70 adenosine nucleotides,
f) optionally a poly(C) tail, preferably consisting of 10 to 200, 10 to 100, 20 to 70, 20 to 60 or 10 to 40 cytosine nucleotides, and
g) optionally a histone stem-loop, optionally comprising or consisting of a nucleic acid sequence corresponding to SEQ ID NO: 3079 or 3080.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

Composition comprising at least one artificial nucleic acid molecule, preferably RNA, according to any one of claims 1 to 30 and a pharmaceutically acceptable carrier and/or excipient.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

Composition according to claim 31 comprising a plurality of at least two artificial nucleic acid molecules according to any one of claims 1 to 30, wherein preferably at least two of said plurality of artificial nucleic acid molecules encode a different antigenic peptide or protein, optionally selected from an antigenic peptide or protein as defined in claim 5, 6 or 7, or a fragment, variant or derivative thereof.

### Claim 33 (depends on 31, 32)

Composition according to claim 31 or 32, wherein said composition is a pharmaceutical composition, optionally a vaccine.

### Claim 34 (depends on 33)

The (pharmaceutical) composition or vaccine according to claim 33, wherein the artificial nucleic acid molecule, preferably RNA, is complexed with one or more cationic or polycationic compounds, preferably with cationic or polycationic polymers, cationic or polycationic peptides or proteins, e.g. protamine, cationic or polycationic polysaccharides and/or cationic or polycationic lipids.

### Claim 35 (depends on 34)

The (pharmaceutical) composition or vaccine according to claim 34, wherein the cationic or polycationic compound is a polymeric carrier.

### Claim 36 (depends on 34)

The (pharmaceutical) composition or vaccine according to claim 34, wherein the N/P ratio of the artificial nucleic acid molecule, preferably RNA, to the one or more cationic or polycationic compounds is in the range of about 0.1 to 10, including a range of about 0.3 to 4, of about 0.5 to 2, of about 0.7 to 2 and of about 0.7 to 1.5.

### Claim 37 (depends on 31, 32, 33, 34, 35, 36)

The (pharmaceutical) composition or vaccine according to any one of claims 31 to 36, wherein the artificial nucleic acid molecule, preferably RNA, is complexed with one or more lipids, thereby forming, lipid nanoparticles, lipoplexes and/or preferably liposomes.

### Claim 38 (depends on 31, 32, 33, 34, 35, 36, 37)

The (pharmaceutical) composition or vaccine according to any one of claims 31 to 37, said composition further comprising a non-coding RNA selected from the group consisting of small interfering RNA (siRNA), antisense RNA (asRNA), circular RNA (circRNA), ribozymes, aptamers, riboswitches, immunostimulating RNA (isRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), microRNA (miRNA), and Piwi-interacting RNA (piRNA).

### Claim 39 (depends on 38)

The (pharmaceutical) composition or vaccine according to claim 38, wherein the immunostimulating RNA comprises at least one RNA sequence according to formula (IS-I) (GlXmGn), formula (IS-II) (ClXmCn), formula (IS-III) (NuGlXmGnNv)a, and/or formula (IS-IV) (NuClXmCnNv)a).

### Claim 40 (depends on 39)

The (pharmaceutical) composition or vaccine according to claim 39, wherein the immunostimulating RNA comprises at least one RNA sequence corresponding to any one of SEQ ID NOs: 2938-3032.

### Claim 41 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The (pharmaceutical) composition or vaccine of any one of claims 31 to 40, wherein the composition comprises a polymeric carrier cargo complex, formed by a polymeric carrier, preferably comprising disulfide-crosslinked cationic peptides, preferably Cys-Arg12, and/or Cys-Arg12-Cys, and an isRNA, preferably comprising or consisting of an RNA sequence corresponding to SEQ ID NOs: 2938-3032.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

Kit, preferably kit of parts, comprising the artificial nucleic acid molecule, preferably RNA, according to any one of claims 1 to 30 or the (pharmaceutical) composition or vaccine according to any one of claims 31 to 41, and optionally a liquid vehicle and/or optionally technical instructions with information on the administration and dosage of the artificial nucleic acid molecule or the composition.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The artificial nucleic acid molecule, preferably RNA, according to any one of claims 1 to 30, the (pharmaceutical) composition or vaccine according to any one of claims 31 to 41, or the kit according to claim 42 for use as a medicament.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The artificial nucleic acid molecule, preferably RNA, according to any one of claims 1 to 30, the (pharmaceutical) composition or vaccine according to any one of claims 31 to 41, or the kit according to claim 42 for use in a method of treatment or prophylaxis of cancer, infectious diseases including viral, bacterial, fungal or protozoal infections, autoimmune diseases, Graft-versus-host disease (GvHD) or allergies.

### Claim 45 (depends on 44)

The artificial nucleic acid molecule, preferably RNA, for the use according to claim 44, wherein said use comprises (a) administering, to a subject in need thereof, said artificial nucleic acid molecule, preferably RNA, said (pharmaceutical) composition or vaccine, or said kit.

### Claim 46 (depends on 45)

The artificial nucleic acid molecule, preferably RNA, for the use according to claim 45, wherein administration is accomplished parenterally, preferably intradermally, subcutaneously, intravenously, intramuscularly, intranodally, transdermally, or intratumorally.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

A method of treating or preventing cancer, autoimmune diseases, or infectious diseases including viral, bacterial, fungal or protozoal infections, wherein the method comprises administering, to a patient in need thereof, an effective amount of the artificial nucleic acid molecule, preferably RNA, according to any one of claims 1 to 30, the (pharmaceutical) composition or vaccine according to any one of claims 31 to 41, or the kit according to claim 42.

### Claim 48 (depends on 44, 45, 46, 47)

The use according to any one of claims 44 to 46, or the method according to claim 47, further comprising subjecting the patient to at least one or more of the following additional therapies: chemotherapy (e.g. first-line or second-line chemotherapy), radiotherapy, chemoradiation (combination of chemotherapy and radiotherapy), kinase inhibitors, antibody therapy and/or checkpoint modulators (e.g. CTLA4 inhibitors, PD1 pathway inhibitors) or inhibitors inducing expression of T cell epitopes associated with impaired peptide processing (TEIPPs).

### Claim 49 (depends on 48)

The use according to claim 48, wherein said additional therapy is effected prior, simultaneously, or subsequently to the administration of said artificial nucleic acid molecule, (pharmaceutical) composition or vaccine, or kit.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

An in vitro cell culture or cell treatment method comprising (a) providing cells in vitro, (b) contacting said cells with the artificial nucleic acid molecule, preferably RNA, according to any one of claims 1 to 30, the (pharmaceutical) composition or vaccine according to any one of claims 31 to 41, or the kit according to claim 42.
